DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial DecompressionPRNewsWire • 02/02/21
DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 MillionPRNewsWire • 01/04/21
DURECT Corporation to Sell its LACTEL® Absorbable Polymer Product Line to Evonik for $15 MillionPRNewsWire • 12/07/20
DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020PRNewsWire • 11/13/20
DURECT Corporation (DRRX) CEO Jim Brown on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/03/20
DURECT Corporation to Participate in the ROTH Capital Partners Healthcare Event "Covid-19 Therapeutics in Development"PRNewsWire • 10/26/20
Durect (DRRX) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/26/20
DURECT Corporation to Participate in Fireside Chat at H.C. Wainwright 4th Annual NASH Investor ConferencePRNewsWire • 09/30/20
DURECT Corporation (DRRX) CEO Jim Brown on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/04/20
DURECT Corporation Announces Second Quarter 2020 Financial Results and Update of ProgramsPRNewsWire • 08/03/20
Gilead Terminates License Agreement for Long-Acting Injectable HIV Investigational ProductPRNewsWire • 06/26/20
DURECT Corporation: DUR-928 May Benefit COVID-19 Patients With Acute Organ InjurySeeking Alpha • 05/13/20
DURECT Corp (DRRX) CEO James Brown on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/12/20
Durect (DRRX) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/28/20
DURECT Corporation (DRRX) CEO Jim Brown on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/04/20